Shahid Mahmud Malik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shahid Mahmud Malik has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Abhinav Humar
Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
2 shared publications - David A. Geller
Department of Surgery, University of Pittsburgh, UPMC Liver Cancer Center, Pittsburgh, PA, USA
2 shared publications - Jaideep Behari
Pittsburgh Liver Research Center, University of Pittsburgh, Pittsburgh, USA
2 shared publications Jawad Ahmad
University of Pittsburgh School of Medicine, Pittsburgh, PA
2 shared publications- Michele Molinari
Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
2 shared publications Abhinav Humar
Thomas E. Starzl Transplantation Institute University of Pittsburgh Medical Center Pittsburgh Pennsylvania USA
1 shared publication
Latest Publications
- 14 October 2026
- Published by SAGE Publications in Journal of Intensive Care Medicine
Acute Alcohol-Associated Hepatitis: The Role of Liver Transplantation
Severe alcohol-associated hepatitis (AH) remains one of the most challenging syndromes in hepatology and critical care, with high short-term mortality despite advances in supportive management. Although corticosteroids remain the only guideline-endorsed pharmacologic therapy shown to improve early survival, their benefit is modest, limited to selected patients, and frequently complicated by infection. Consequently, contemporary management extends well beyond corticosteroid therapy and requires meticulous supportive care, nutritional optimization, infection surveillance, management of portal hypertensive complications and acute-on-chronic liver failure (ACLF), and early multidisciplinary involvement. This review summarizes the current evidence regarding the diagnosis, prognostic assessment, and medical management of severe AH. Key prognostic models, including MELD, Maddrey Discriminant Function, and the Lille score, are discussed together with evolving evidence supporting individualized corticosteroid use and emerging investigational therapies. Particular emphasis is placed on critically ill patients with ACLF, in whom extrahepatic organ failure often supersedes liver dysfunction as the principal determinant of outcome. The review also examines the evolving role of early liver transplantation (LT), one of the most important paradigm shifts in modern transplant hepatology. Contemporary approaches to patient selection, psychosocial assessment, relapse-risk evaluation, living donor transplantation, and the management of patients with catastrophic AH are discussed, along with ethical considerations surrounding organ allocation, medical urgency, and stewardship of scarce donor organs. Despite important advances in supportive care and transplantation, severe AH continues to carry substantial mortality. Optimizing outcomes requires timely diagnosis, multidisciplinary management, careful selection for medical therapy, and early recognition of patients unlikely to recover without liver transplantation.
- 14 October 2026
- Published by SAGE Publications in Journal of Intensive Care Medicine
Acute Alcohol-Associated Hepatitis: The Role of Liver Transplantation
Severe alcohol-associated hepatitis (AH) remains one of the most challenging syndromes in hepatology and critical care, with high short-term mortality despite advances in supportive management. Although corticosteroids remain the only guideline-endorsed pharmacologic therapy shown to improve early survival, their benefit is modest, limited to selected patients, and frequently complicated by infection. Consequently, contemporary management extends well beyond corticosteroid therapy and requires meticulous supportive care, nutritional optimization, infection surveillance, management of portal hypertensive complications and acute-on-chronic liver failure (ACLF), and early multidisciplinary involvement. This review summarizes the current evidence regarding the diagnosis, prognostic assessment, and medical management of severe AH. Key prognostic models, including MELD, Maddrey Discriminant Function, and the Lille score, are discussed together with evolving evidence supporting individualized corticosteroid use and emerging investigational therapies. Particular emphasis is placed on critically ill patients with ACLF, in whom extrahepatic organ failure often supersedes liver dysfunction as the principal determinant of outcome. The review also examines the evolving role of early liver transplantation (LT), one of the most important paradigm shifts in modern transplant hepatology. Contemporary approaches to patient selection, psychosocial assessment, relapse-risk evaluation, living donor transplantation, and the management of patients with catastrophic AH are discussed, along with ethical considerations surrounding organ allocation, medical urgency, and stewardship of scarce donor organs. Despite important advances in supportive care and transplantation, severe AH continues to carry substantial mortality. Optimizing outcomes requires timely diagnosis, multidisciplinary management, careful selection for medical therapy, and early recognition of patients unlikely to recover without liver transplantation.
- 22 October 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (6) , 1301
Colonic Coil Conundrum
- 22 October 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (6) , 1301
Colonic Coil Conundrum
- Open Access
- 1 January 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (1)
Survival benefit associated with liver transplantation for hepatocellular carcinoma based on tumor burden scores at listing
Introduction: Liver transplantation (LT) provides significant survival benefits to patients with unresectable HCC. In the United States, organ allocation policies for HCCs within the United Network for Organ Sharing criteria do not prioritize patients based on their differences in oncological characteristics. This study assessed whether transplant-associated survival benefits (TASBs) vary among patients with different tumor burden scores (TBS) measured at the time of listing. Methods: We analyzed data from adults applying for HCC MELD exception points between 2002 and 2019, with follow-up until December 2023, using the Scientific Registry of Transplant Recipients. TBS was determined based on the largest tumor diameter and number of HCCs. Patients were categorized into low (≤3), intermediate (3.1–5), and high (>5) TBS groups. TASB was measured as the difference in 5-year survival with and without LT. Results: This study included 36,634 LT candidates. High-TBS patients had higher waitlist dropout rates and marginally lower post-transplant survival, resulting in a significantly greater TASB. The 5-year TASB for the low, intermediate, and high TBS groups were 15.7, 22.1, and 25.0 months, respectively. The adjusted survival benefit expressed in 5-year survival differences was 21.9%, 34.5%, and 39.4% in the low, intermediate, and high TBS groups, respectively (p<0.001). Conclusions: Higher TBS during listing correlates with greater LT benefits for patients with unresectable HCC within UNOS criteria. We conclude that organ allocation policies in the United States should prioritize patients with high TBS due to their increased risk of dropout and comparable post-transplant survival when compared to patients with less advanced tumors.
- 1 January 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (1)
Open AccessSurvival benefit associated with liver transplantation for hepatocellular carcinoma based on tumor burden scores at listing
Introduction: Liver transplantation (LT) provides significant survival benefits to patients with unresectable HCC. In the United States, organ allocation policies for HCCs within the United Network for Organ Sharing criteria do not prioritize patients based on their differences in oncological characteristics. This study assessed whether transplant-associated survival benefits (TASBs) vary among patients with different tumor burden scores (TBS) measured at the time of listing. Methods: We analyzed data from adults applying for HCC MELD exception points between 2002 and 2019, with follow-up until December 2023, using the Scientific Registry of Transplant Recipients. TBS was determined based on the largest tumor diameter and number of HCCs. Patients were categorized into low (≤3), intermediate (3.1–5), and high (>5) TBS groups. TASB was measured as the difference in 5-year survival with and without LT. Results: This study included 36,634 LT candidates. High-TBS patients had higher waitlist dropout rates and marginally lower post-transplant survival, resulting in a significantly greater TASB. The 5-year TASB for the low, intermediate, and high TBS groups were 15.7, 22.1, and 25.0 months, respectively. The adjusted survival benefit expressed in 5-year survival differences was 21.9%, 34.5%, and 39.4% in the low, intermediate, and high TBS groups, respectively (p<0.001). Conclusions: Higher TBS during listing correlates with greater LT benefits for patients with unresectable HCC within UNOS criteria. We conclude that organ allocation policies in the United States should prioritize patients with high TBS due to their increased risk of dropout and comparable post-transplant survival when compared to patients with less advanced tumors.
- 25 November 2024
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 70 (1) , 399-405
Challenges and Opportunities in the Adoption of p-TIPS for Acute Variceal Bleeding: Insights from a US Tertiary Center
Background and Aims Since the overwhelmingly positive results of the ‘early use of TIPS’ published in 2010, studies in Europe and Asia have confirmed early/pre-emptive transjugular intrahepatic portosystemic shunt (p-TIPS) in high-risk patients with acute variceal bleed (AVB) reduces treatment failure and mortality compared to standard of care (SOC). There are no studies evaluating p-TIPS in a US cohort. Methods A review of patients with cirrhosis from June 2010 to June 2020 with AVB was conducted from a single large US center. Results Of 745 cirrhotic patients with AVB, 18% met criteria for p-TIPS. Alcohol and HCV accounted for 75% of etiology; 13% MASLD. The mean MELD-Na score in our cohort was 24, which is ten points higher than reported in the literature for over 600 p-TIPS cases. Only 9 patients underwent p-TIPS. Patients undergoing p-TIPS were less likely to have MASLD, more likely to be female and less likely to have PSE at baseline. One-year mortality in the SOC group (including patients undergoing ‘rescue TIPS’) was 53% versus 0% for p-TIPS (p = 0.01). Conclusion Our observation suggests hesitancy among providers to recommend p-TIPS, likely due to concerns regarding a ‘sicker’ patient population. The current SOC in high-risk patients remain suboptimal. Limited data, including our own, suggest that p-TIPS may confer a survival benefit even in patients with high MELD. However, the recommendation of p-TIPS in such patients necessitates validation of its safety and efficacy. Consequently, we advocate for a RCT in the US to conclusively assess the utility of p-TIPS in this context. Until such evidence is established, it is likely that underutilization of this life-saving intervention will persist.
- 25 November 2024
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 70 (1) , 399-405
Challenges and Opportunities in the Adoption of p-TIPS for Acute Variceal Bleeding: Insights from a US Tertiary Center
Background and Aims Since the overwhelmingly positive results of the ‘early use of TIPS’ published in 2010, studies in Europe and Asia have confirmed early/pre-emptive transjugular intrahepatic portosystemic shunt (p-TIPS) in high-risk patients with acute variceal bleed (AVB) reduces treatment failure and mortality compared to standard of care (SOC). There are no studies evaluating p-TIPS in a US cohort. Methods A review of patients with cirrhosis from June 2010 to June 2020 with AVB was conducted from a single large US center. Results Of 745 cirrhotic patients with AVB, 18% met criteria for p-TIPS. Alcohol and HCV accounted for 75% of etiology; 13% MASLD. The mean MELD-Na score in our cohort was 24, which is ten points higher than reported in the literature for over 600 p-TIPS cases. Only 9 patients underwent p-TIPS. Patients undergoing p-TIPS were less likely to have MASLD, more likely to be female and less likely to have PSE at baseline. One-year mortality in the SOC group (including patients undergoing ‘rescue TIPS’) was 53% versus 0% for p-TIPS (p = 0.01). Conclusion Our observation suggests hesitancy among providers to recommend p-TIPS, likely due to concerns regarding a ‘sicker’ patient population. The current SOC in high-risk patients remain suboptimal. Limited data, including our own, suggest that p-TIPS may confer a survival benefit even in patients with high MELD. However, the recommendation of p-TIPS in such patients necessitates validation of its safety and efficacy. Consequently, we advocate for a RCT in the US to conclusively assess the utility of p-TIPS in this context. Until such evidence is established, it is likely that underutilization of this life-saving intervention will persist.
- Open Access
- 25 July 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (7) , e15340
Expedited liver transplantation as first‐line therapy for severe alcohol hepatitis: ELFSAH; deferring corticosteroids in the sickest subset of patients
Background & aims: Severe alcohol‐associated hepatitis (SAH) represents a lethal subset of alcohol‐associated liver disease. Although corticosteroids are recommended by guidelines, their efficacy and safety remain questionable and so liver transplantation (LT) has been increasingly utilized. The timing and indication of corticosteroid use, specifically in patients being considered for LT requires further clarification.Methods: A retrospective analysis was conducted on 256 patients with SAH between 2018 and 2022 at a single US center.Results: Twenty of these patients underwent LT. Of the 256 patients, 38% had what we termed “catastrophic” SAH, defined as a MELD‐Na ≥35 and/or discriminant function (DF) ≥100, which carried a mortality of 90% without LT. Compared with 100 matched controls, patients undergoing LT exhibited a one‐year survival rate of 100% versus 35% (p < .0005). LT provided an absolute risk reduction of 65%, with a number needed to treat of 1.5. Steroid utilization in the entire cohort was 19% with 60% developing severe complications. Patients administered steroids were younger with lower MELD and DF scores. Only 10% of those prescribed steroids derived a favorable response. Sustained alcohol use post‐LT was 20%.Conclusions: We propose ELFSAH: Expedited LT as First Line Therapy for SAH; challenging the current paradigm with recommendations to defer steroids in patients with “catastrophic” SAH (defined as: MELD‐Na ≥35 and/or DF ≥100). Patients should be seen urgently by hepatology, transplant surgery, psychiatry and social work. Patients without an absolute contraindication should be referred for LT as first‐line therapy during their index admission.
- 25 July 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (7) , e15340
Open AccessExpedited liver transplantation as first‐line therapy for severe alcohol hepatitis: ELFSAH; deferring corticosteroids in the sickest subset of patients
Background & aims: Severe alcohol‐associated hepatitis (SAH) represents a lethal subset of alcohol‐associated liver disease. Although corticosteroids are recommended by guidelines, their efficacy and safety remain questionable and so liver transplantation (LT) has been increasingly utilized. The timing and indication of corticosteroid use, specifically in patients being considered for LT requires further clarification.Methods: A retrospective analysis was conducted on 256 patients with SAH between 2018 and 2022 at a single US center.Results: Twenty of these patients underwent LT. Of the 256 patients, 38% had what we termed “catastrophic” SAH, defined as a MELD‐Na ≥35 and/or discriminant function (DF) ≥100, which carried a mortality of 90% without LT. Compared with 100 matched controls, patients undergoing LT exhibited a one‐year survival rate of 100% versus 35% (p < .0005). LT provided an absolute risk reduction of 65%, with a number needed to treat of 1.5. Steroid utilization in the entire cohort was 19% with 60% developing severe complications. Patients administered steroids were younger with lower MELD and DF scores. Only 10% of those prescribed steroids derived a favorable response. Sustained alcohol use post‐LT was 20%.Conclusions: We propose ELFSAH: Expedited LT as First Line Therapy for SAH; challenging the current paradigm with recommendations to defer steroids in patients with “catastrophic” SAH (defined as: MELD‐Na ≥35 and/or DF ≥100). Patients should be seen urgently by hepatology, transplant surgery, psychiatry and social work. Patients without an absolute contraindication should be referred for LT as first‐line therapy during their index admission.
- 26 April 2024
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 11 (5) , e01336
Porto-Sinusoidal Vascular Disease in Congenital Erythropoietic Porphyria Needing Liver Transplantation
Ia due to deficiency of uroporphyrinogen III synthase, mostly results in cutaneous manifestations. There are reports of liver involvement including varying degree of fibrosis in patients with CEP. We report a unique case of a patient with CEP who developed porto-sinusoidal vascular disease with complications of portal hypertension that necessitated liver transplantation....
- 26 April 2024
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 11 (5) , e01336
Porto-Sinusoidal Vascular Disease in Congenital Erythropoietic Porphyria Needing Liver Transplantation
Ia due to deficiency of uroporphyrinogen III synthase, mostly results in cutaneous manifestations. There are reports of liver involvement including varying degree of fibrosis in patients with CEP. We report a unique case of a patient with CEP who developed porto-sinusoidal vascular disease with complications of portal hypertension that necessitated liver transplantation....
- 12 September 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (10) , e15130
A novel scoring system to predict survival in cirrhotic patients undergoing isolated lung transplantation: The PENS‐CEPT score
Cirrhosis is usually regarded as a contraindication to isolated lung transplantation (ILT). We sought to determine which patients with cirrhosis could safely undergo ILT. Based on a retrospective analysis of patients with cirrhosis who underwent ILT at our center between 2007 and 2020, we developed an exclusionary algorithm (PENS‐CEPT: Pittsburgh ExclusioN Score in Cirrhotics Evaluated for Pulmonary Transplant) to help determine which patients can undergo ILT with minimal incurred risk from their underlying liver disease. The score utilizes a combination of readily available clinical data and the presence (or absence) of spontaneous portosystemic shunts on preoperative cross‐sectional imaging. Sixteen patients underwent ILT with a diagnosis of cirrhosis: nine with cystic fibrosis. On univariate analysis, only our model was able to predict 1 year survival. Of the nine patients that would have been approved using our model, there was only one short term death. Of the seven patients that would have been rejected by the model, all but one died within the first year with six dying of complications from liver failure. We are proposing a simple score utilizing routine clinical parameters and pre‐operative imaging to determine the safety of ILT in cirrhotic patients. Further studies are required to validate this scoring system with the goal of safely increasing the opportunity for cirrhotic patients who would otherwise be rejected for ILT.
- 12 September 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (10) , e15130
A novel scoring system to predict survival in cirrhotic patients undergoing isolated lung transplantation: The PENS‐CEPT score
Cirrhosis is usually regarded as a contraindication to isolated lung transplantation (ILT). We sought to determine which patients with cirrhosis could safely undergo ILT. Based on a retrospective analysis of patients with cirrhosis who underwent ILT at our center between 2007 and 2020, we developed an exclusionary algorithm (PENS‐CEPT: Pittsburgh ExclusioN Score in Cirrhotics Evaluated for Pulmonary Transplant) to help determine which patients can undergo ILT with minimal incurred risk from their underlying liver disease. The score utilizes a combination of readily available clinical data and the presence (or absence) of spontaneous portosystemic shunts on preoperative cross‐sectional imaging. Sixteen patients underwent ILT with a diagnosis of cirrhosis: nine with cystic fibrosis. On univariate analysis, only our model was able to predict 1 year survival. Of the nine patients that would have been approved using our model, there was only one short term death. Of the seven patients that would have been rejected by the model, all but one died within the first year with six dying of complications from liver failure. We are proposing a simple score utilizing routine clinical parameters and pre‐operative imaging to determine the safety of ILT in cirrhotic patients. Further studies are required to validate this scoring system with the goal of safely increasing the opportunity for cirrhotic patients who would otherwise be rejected for ILT.
- Open Access
- 3 July 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (7)
Incidence of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis or advanced liver fibrosis
Background: HCC can develop in the absence of cirrhosis in patients with NAFLD. We aimed to estimate the incidence of HCC in patients with NAFLD with and without cirrhosis or advanced liver fibrosis. Methods: We performed a cohort study to determine the incidence of HCC in patients with NAFLD identified by the International Classification of Diseases 9/10 codes in the electronic health records of a US health care system between 2004 and 2018. The incidence of HCC was stratified by the presence or absence of cirrhosis and by the Fibrosis-4 index (FIB-4) at the time of HCC diagnosis. Results: Of 47,165 patients with NAFLD aged 40–89 years, 981 (2.1%) developed HCC (mean follow-up 3.4 y). Among patients with HCC, 842 (85.8%) had cirrhosis, while 139 (14.2%) did not. Of the 139 patients with HCC without cirrhosis-related diagnostic codes, 26 (2.7%) had FIB-4 >2.67 (advanced fibrosis likely), whereas 43 (4.4%) had FIB-4 < 1.30 (excluding advanced fibrosis). The annual incidence of HCC in patients with NAFLD with and without cirrhosis was 23.6 and 1.1 per 1000 person-years, respectively. Among patients without cirrhosis, the annual incidence of HCC was 2.8 per 1000 person-years with FIB-4 >2.67 and 0.7 per 1000 person-years with FIB-4 <1.30. Patients with NAFLD and cirrhosis were 31.8 times (95% CI, 23.3–43.4) more likely to develop HCC than those without cirrhosis and FIB-4 <1.30, after adjustment for age and sex. Conclusions: Patients with NAFLD without cirrhosis nor advanced fibrosis have a low incidence of HCC.
- 3 July 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (7)
Open AccessIncidence of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis or advanced liver fibrosis
Background: HCC can develop in the absence of cirrhosis in patients with NAFLD. We aimed to estimate the incidence of HCC in patients with NAFLD with and without cirrhosis or advanced liver fibrosis. Methods: We performed a cohort study to determine the incidence of HCC in patients with NAFLD identified by the International Classification of Diseases 9/10 codes in the electronic health records of a US health care system between 2004 and 2018. The incidence of HCC was stratified by the presence or absence of cirrhosis and by the Fibrosis-4 index (FIB-4) at the time of HCC diagnosis. Results: Of 47,165 patients with NAFLD aged 40–89 years, 981 (2.1%) developed HCC (mean follow-up 3.4 y). Among patients with HCC, 842 (85.8%) had cirrhosis, while 139 (14.2%) did not. Of the 139 patients with HCC without cirrhosis-related diagnostic codes, 26 (2.7%) had FIB-4 >2.67 (advanced fibrosis likely), whereas 43 (4.4%) had FIB-4 < 1.30 (excluding advanced fibrosis). The annual incidence of HCC in patients with NAFLD with and without cirrhosis was 23.6 and 1.1 per 1000 person-years, respectively. Among patients without cirrhosis, the annual incidence of HCC was 2.8 per 1000 person-years with FIB-4 >2.67 and 0.7 per 1000 person-years with FIB-4 <1.30. Patients with NAFLD and cirrhosis were 31.8 times (95% CI, 23.3–43.4) more likely to develop HCC than those without cirrhosis and FIB-4 <1.30, after adjustment for age and sex. Conclusions: Patients with NAFLD without cirrhosis nor advanced fibrosis have a low incidence of HCC.
- Open Access
- 1 April 2023
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 10 (4) , e01038
Cemiplimab-Associated Sinusoidal Obstruction Syndrome
A 58-year-old woman developed new-onset recurrent ascites after the recent initiation of cemiplimab for the treatment of advanced basal cell carcinoma. A comprehensive serological workup for viral, metabolic, and autoimmune causes was unrevealing. Transjugular liver biopsy demonstrated parenchymal changes consistent with a diagnosis of sinusoidal obstruction syndrome. While this is a condition commonly observed in patients after hematopoietic stem cell transplantation or use of chemotherapeutic agents, it should also be considered in patients who develop new-onset liver dysfunction after the initiation of checkpoint inhibitors.
- 1 April 2023
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 10 (4) , e01038
Open AccessCemiplimab-Associated Sinusoidal Obstruction Syndrome
A 58-year-old woman developed new-onset recurrent ascites after the recent initiation of cemiplimab for the treatment of advanced basal cell carcinoma. A comprehensive serological workup for viral, metabolic, and autoimmune causes was unrevealing. Transjugular liver biopsy demonstrated parenchymal changes consistent with a diagnosis of sinusoidal obstruction syndrome. While this is a condition commonly observed in patients after hematopoietic stem cell transplantation or use of chemotherapeutic agents, it should also be considered in patients who develop new-onset liver dysfunction after the initiation of checkpoint inhibitors.
- Open Access
- 13 December 2021
- Published by CrossLinks International Publishers in Pakistan BioMedical Journal
- Vol. 5 (1)
Effect of diabetes mellitus and glycemic control on the prognosis of invasive bladder cancer
A patient's prognosis for cancer treatment is thought to be affected by their presence of diabetes mellitus (DM). Epidemiological studies show that type 2 diabetes raises the risk of a wide range of cancers, including colorectal, breast, endometrial, and hepatocellular carcinoma. Findings for bladder cancer were hard to comprehend and thus no proof has been presented. Objectives: Invasive bladder cancer prognosis will be examined in this study in relation to diabetes and glycemic control. Methodology of the study: Researcher performed this cross-sectional study between January 2011 and January 2021 at Galway Hospital, Ireland and University Lahore Teaching Hospital in Lahore, Pakistan. The data was collected from 136 bladder cancer patients during the period of these five years. The data was collected with the permission of ethical committee of hospitals. Patients with last two years of DM were include in this study. Results: The study was completed by 136 patients. Their mean age was 53.2 ± 8.4 years (range: 36-61 years). There were more males than females (60% vs. 40%). Table 1 provides an overview of their clinical and demographic data. Conclusion: Diabetes mellitus is a metabolic condition that affects all main bodily systems, although it is not linked to the advancement of bladder cancer, according to the findings. However, poor glycemic management is linked to a greater recurrence rate. In patients with DM and invasive bladder cancer, glycemic management should be one of the therapy aims.
- 13 December 2021
- Published by CrossLinks International Publishers in Pakistan BioMedical Journal
- Vol. 5 (1)
Open AccessEffect of diabetes mellitus and glycemic control on the prognosis of invasive bladder cancer
A patient's prognosis for cancer treatment is thought to be affected by their presence of diabetes mellitus (DM). Epidemiological studies show that type 2 diabetes raises the risk of a wide range of cancers, including colorectal, breast, endometrial, and hepatocellular carcinoma. Findings for bladder cancer were hard to comprehend and thus no proof has been presented. Objectives: Invasive bladder cancer prognosis will be examined in this study in relation to diabetes and glycemic control. Methodology of the study: Researcher performed this cross-sectional study between January 2011 and January 2021 at Galway Hospital, Ireland and University Lahore Teaching Hospital in Lahore, Pakistan. The data was collected from 136 bladder cancer patients during the period of these five years. The data was collected with the permission of ethical committee of hospitals. Patients with last two years of DM were include in this study. Results: The study was completed by 136 patients. Their mean age was 53.2 ± 8.4 years (range: 36-61 years). There were more males than females (60% vs. 40%). Table 1 provides an overview of their clinical and demographic data. Conclusion: Diabetes mellitus is a metabolic condition that affects all main bodily systems, although it is not linked to the advancement of bladder cancer, according to the findings. However, poor glycemic management is linked to a greater recurrence rate. In patients with DM and invasive bladder cancer, glycemic management should be one of the therapy aims.